SLE Peripheral Blood B Cell, T Cell and Myeloid Cell Transcriptomes Display Unique Profiles and Each Subset Contributes to the Interferon Signature-Reference-Cited by-同舟云学术

SLE Peripheral Blood B Cell, T Cell and Myeloid Cell Transcriptomes Display Unique Profiles and Each Subset Contributes to the Interferon Signature

Published:2013-06-24 Issue:6 Volume:8 Page:e67003
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Becker Amy M.,Dao Kathryn H.,Han Bobby Kwanghoon,Kornu Roger,Lakhanpal Shuchi,Mobley Angela B.,Li Quan-Zhen,Lian Yun,Wu Tianfu,Reimold Andreas M.,Olsen Nancy J.,Karp David R.,Chowdhury Fatema Z.,Farrar J. David,Satterthwaite Anne B.,Mohan Chandra,Lipsky Peter E.,Wakeland Edward K.,Davis Laurie S.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference77 articles.

1. Collaboration, genetic associations, and lupus erythematosus;MK Crow;N Engl J Med,2008

2. Clinical features of systemic lupus erythematosus;M Petri;Curr Opin Rheumatol,1995

3. Development of autoantibodies before the clinical onset of systemic lupus erythematosus;MR Arbuckle;N Engl J Med,2003

4. Ribosomal P autoantibodies are present before SLE onset and are directed against non-C-terminal peptides;LD Heinlen;J Mol Med (Berl),2010

5. Interferon-alpha induces unabated production of short-lived plasma cells in pre-autoimmune lupus-prone (NZBxNZW)F1 mice but not in BALB/c mice;A Mathian;Eur J Immunol,2011

Cited by 167 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Crosstalk and Prospects of TBK1 in Inflammation;Immunological Investigations;2024-08-28

2. Type I interferon gene expression signature as a marker to predict response to cyclophosphamide based treatment in proliferative lupus nephritis;Lupus;2024-07-20

3. Toll-like Receptor Homologue CD180 Ligation of B Cells Upregulates Type I IFN Signature in Diffuse Cutaneous Systemic Sclerosis;International Journal of Molecular Sciences;2024-07-20

4. Crucial Roles of RSAD2/viperin in Immunomodulation, Mitochondrial Metabolism and Autoimmune Diseases;Inflammation;2024-06-23

5. A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis;Arthritis Research & Therapy;2024-06-06